These results confirm our hypothesis that increased gene expression of sialin in some tissues (SM, stomach, liver, and eAT) is a counterregulatory response for reduced NO bioavailability in rats with T2D. This evidence concerns the gene SLC17A5 and type 2 diabetes mellitus.